Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices

Expert Opinion on Drug Delivery
Smrithi PadmakumarMansoor M Amiji

Abstract

Epithelial ovarian cancer (EOC) remains to be the most lethal of all gynecological malignancies mainly due to its asymptomatic nature. The late stages are manifested with predominant metastases confined to the peritoneal cavity. Although there has been a substantial progress in the treatment avenue with different therapeutic interventions, the overall survival rate of patients remain poor due to relapse and drug resistance. The pharmacokinetic advantages offered by intraperitoneal (IP) chemotherapy due to peritoneal-plasma barrier can be potentially exploited for EOC relapse treatment. The ability to retain high concentrations of chemo-drugs with high AUC peritoneum/plasma for prolonged durations in the peritoneal cavity can be utilized effectively through the clinical adoption of drug delivery systems (DDSs) which obviates the need for indwelling catheters. The metronomic dosing strategy could enhance anti-tumor efficacy with a continuous, low dose of chemo-drugs providing minimal systemic toxicity. The development of a feasible, non-catheter based, IP DDS, retaining the peritoneal-drug levels, with less systemic levels could offer significant survival advantages as a patient-compliant therapeutic strategy. Suturable-implantab...Continue Reading

References

Dec 9, 1983·JAMA : the Journal of the American Medical Association·R C YoungJ P Smith
Jan 1, 1996·Cancer Treatment and Research·P Jacquet, P H Sugarbaker
Apr 2, 1997·Journal of the National Cancer Institute·R L Dedrick, M F Flessner
Jul 31, 1998·European Radiology·J C Healy, R H Reznek
Mar 30, 2001·Gynecologic Oncology·S MakhijaR Barakat
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun
Mar 21, 2002·The Lancet Oncology·G Gasparini
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Jul 25, 2003·Cancer Chemotherapy and Pharmacology·Faheez MohamedPaul H Sugarbaker
Jul 30, 2003·Cancer Metastasis Reviews·C Pablo CarmignaniPaul H Sugarbaker
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Feb 5, 2005·American Journal of Physiology. Renal Physiology·Michael F Flessner
May 3, 2005·Nature Reviews. Cancer·Honami Naora, Denise J Montell
May 4, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Emmanuel A HoMicheline Piquette-Miller
Jan 21, 2006·Journal of Biomedical Materials Research. Part a·Daniel S KohaneRobert Langer
Aug 9, 2006·Current Opinion in Oncology·Chad A Hamilton, Jonathan S Berek
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jyotsnabaran HalderAnil K Sood
Oct 10, 2006·Gynecologic Oncology·Edward L Trimble, Ronald D Alvarez
Nov 23, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Emmanuel A HoMicheline Piquette-Miller
Nov 23, 2006·Lancet·Richard QuekEng Huat Tan
Apr 21, 2007·Pharmaceutical Research·Max TsaiJessie L-S Au
May 18, 2007·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Eelco de Bree, Dimitris D Tsiftsis
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gautam RaoMace L Rothenberg
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claes Tropé, Janne Kaern
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ping-Yu LiuMaurie Markman
Jan 1, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Patrick Lim SooChristine Allen
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S B Howell
Mar 19, 2008·Molecular Cancer Therapeutics·Vessela VassilevaMicheline Piquette-Miller
Jun 13, 2008·Advances in Experimental Medicine and Biology·Katherine F RobyPaul F Terranova
Jun 14, 2008·International Journal of Pharmaceutics·Justin GrantChristine Allen
Sep 11, 2008·The Journal of Pharmacology and Experimental Therapeutics·Ze LuJessie L-S Au
Oct 18, 2008·Journal of the National Comprehensive Cancer Network : JNCCN·Robert J MorganUNKNOWN National Comprehensive Cancer Network
Mar 12, 2009·Current Drug Discovery Technologies·Kurt Van der SpeetenPaul H Sugarbaker
Apr 1, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yang YangQiang Zhang
Apr 17, 2009·Current Oncology·O G ScharovskyV R Rozados
Apr 28, 2009·Biomaterials·Raquel De SouzaMicheline Piquette-Miller

❮ Previous
Next ❯

Citations

Mar 7, 2020·Expert Opinion on Drug Delivery·Wim CeelenKatrien Remaut
Aug 17, 2019·Current Drug Delivery·Smrithi Padmakumar, Deepthy Menon
May 18, 2018·Molecular Cancer·Yanyu PangGuan Jiang
Mar 15, 2020·Drug Delivery and Translational Research·Maie S TahaMansoor M Amiji
Sep 20, 2021·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Dingxi LiHongtu Chao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.